Company: STAA
Filing Date: 2025-04-24
Form Type: DEF 14A
Source: 0000950170-25-058174
Chunk: 33

Company: STAAR SURGICAL CO
Filing Date: 2025-04-24
Form: DEF 14A
Chunk 33
---
 such as Japan, South Korea, and the United States                
 •Missed minimum threshold achievement levels for both revenue and adjusted EBITDA per share* goals under cash bonus and PSU programs                       | •Funded annual cash bonus program at zero for all executives, resulting in executives receiving no annual bonus payout   
 •All PSUs granted in 2024 achieved zero payout, resulting in forfeiture and termination of the entire award              
 •After conducting a search, the Compensation Committee engaged a new independent compensation consultant                 
 •Adopted updated Corporate Governance Guidelines and Stock Ownership Guidelines, as well as a new Insider Trading Policy |
| •Appointed Mr. Farrell, who has served as a member of the STAAR Board since 2016, as CEO to succeed Thomas Frinzi                                          
 •Promoted Warren Foust to President and Chief Operating Officer                                                                                            
 •Elevated Magda Michna, PhD to Chief Development Officer and Nathaniel Sisitsky, Esq. to Chief Legal Officer                                               
 •Appointed Deborah Andrews, a former CFO of STAAR, as Interim CFO to succeed Patrick Williams; STAAR is conducting a search for a permanent CFO            | •Established new incentive programs:                                                                                     
 ▪Annual cash bonus program includes goals for revenue, cost controls, gross profit margin, and strategic measures        
 ▪Equity awards granted to executives in a mix of 50% PSUs and 50% restricted stock units (“RSUs”)                        
 ▪PSUs granted subject to achievement of multi-year revenue growth                                                        
 •Used this performance-oriented pay approach to establish a compensation package for our new CEO                         |

* Adjusted EBITDA per share is a non-GAAP financial measure. Information and reconciliations are provided in the Appendix. 2024 Business Highlights While STAAR faced challenges in fiscal 2024, we continued to drive awareness of our advanced lens-based vision correction technology and invest to build a foundation for future growth.

| In March 2024, we celebrated a major milestone for STAAR - over 3 million of our Implantable Collamer® Lenses sold worldwide | In April 2024, we launched STAAR University, which offers surgeons access to data, publications, and resources to support clinical confidence | In September 2024, we opened a new EVO Experience Center at our headquarters in California to serve as a hub for hands-on training and education |

| 2025 Proxy Statement | – 25 – |

#### –Compensation Discussion and Analysis–
STAAR has outstanding products